Soligenix, Inc. Common Stock (NASDAQ:SNGX) shares hit a new 52-week low during mid-day trading on Tuesday . The company traded as low as $1.38 and last traded at $1.39, with a volume of 800 shares changing hands. The stock had previously closed at $1.41.
A number of research analysts have issued reports on SNGX shares. Maxim Group set a $5.00 price objective on shares of Soligenix, Inc. Common Stock and gave the company a “buy” rating in a research report on Friday, May 11th. ValuEngine raised shares of Soligenix, Inc. Common Stock from a “sell” rating to a “hold” rating in a research report on Saturday, June 2nd. Finally, HC Wainwright set a $3.00 price objective on shares of Soligenix, Inc. Common Stock and gave the company a “hold” rating in a research report on Friday, March 16th.
Soligenix, Inc. Common Stock (NASDAQ:SNGX) last released its earnings results on Friday, May 11th. The biopharmaceutical company reported ($0.27) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.29) by $0.02. The firm had revenue of $1.10 million for the quarter. Soligenix, Inc. Common Stock had a negative net margin of 149.71% and a negative return on equity of 182.10%. sell-side analysts predict that Soligenix, Inc. Common Stock will post -1.1 EPS for the current year.
Soligenix, Inc. Common Stock Company Profile
Soligenix, Inc, a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, BioTherapeutics and Vaccines/BioDefense. The BioTherapeutics segment develops SGX301, a photodynamic therapy, which is in Phase III clinical trial to treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that has completed Phase II clinical trial to treat oral mucositis in head and neck cancer.
Receive News & Ratings for Soligenix Inc. Common Stock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soligenix Inc. Common Stock and related companies with MarketBeat.com's FREE daily email newsletter.